..."Boehringer In-licenses Anti-SIRPA Checkpoint Inhibitor" ). GCAR begins world's first GBM adaptive clinical trial The Global Coalition for Adaptive Research...
...BAY 73-4506, DAST Inhibitor) trilaciclib (G1T28, iv g1t28-1) zanubrutinib (BGB-3111) Allergan plc AstraZeneca plc Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH G1 Therapeutics Inc. Global Coalition for Adaptive Research Ironwood...

...evidence that will help us to improve the way we write regulatory policy.” I-SPY, the Global Coalition for Adaptive Research...
...Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. European Medicines Agency (EMA), Amsterdam, The Netherlands Global Coalition for Adaptive Research...

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...hepatocellular carcinoma (HCC). It is a dual acting signal transduction (DAST) inhibitor of multiple kinases. Global Coalition for Adaptive Research...

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be the first therapy to...
...DAST) inhibitor of multiple kinases. Jennie Walters Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Bayer AG Cure Brain Cancer Foundation Global Coalition for Adaptive Research National...